Nephrology

Treating TINU: Medications and Managing Side Effects

At a Glance

TINU treatment is tailored to kidney and eye inflammation, usually starting with corticosteroids. Steroids must be reduced slowly, with regular eye, kidney, and laboratory checks; medicines that reduce steroid use may be added when inflammation persists or side effects are severe.

The goal of treating TINU syndrome is to quiet the immune system’s attack on the kidneys and eyes as quickly as possible. Because there is no single “official” treatment plan, doctors customize your care based on which part of your body—the kidneys or the eyes—is more severely affected at the time ^[1]^[2].

First-Line Treatment: Corticosteroids

Corticosteroids (often just called “steroids”) are the most common first-line treatment. They work by rapidly reducing inflammation across the whole body ^[1].

For the Kidneys: Doctors usually prescribe systemic steroids (oral pills like prednisone). In severe cases, high-dose “pulses” of steroids may be given through an IV for a few days to protect kidney function ^[3]^[4].
For the Eyes: Topical steroids (eye drops) are the standard for treating the front part of the eye (anterior uveitis). These drops are used many times a day at first and then slowly reduced ^[5]^[6]. If the inflammation is in the back of the eye, oral steroids or injections near the eye may be needed ^[7]^[8].

The Importance of the Slow Taper

Steroids must be tapered—gradually reduced over weeks or months—but the reasons differ based on the medication type ^[6].

Systemic (Oral) Steroids: Prolonged oral steroids suppress your body’s natural ability to make cortisol (adrenal suppression). They must be tapered slowly to allow your adrenal glands to recover safely, as well as to prevent a systemic relapse.
Topical (Eye Drop) Steroids: Eye drops are tapered primarily under an ophthalmologist’s direction to prevent the ocular inflammation from rebounding.
Relapse Risk: About 50% of people with TINU may experience a relapse of eye inflammation during or shortly after the taper ^[5]. In some cases, the kidneys improve quickly while the eyes continue to flare, requiring different tapering schedules for the drops versus the pills ^[6]^[9].
Never change your dose or stop either oral steroids or eye drops without direct instructions from your treating doctor.

Potential Side Effects and Harms

While steroids are powerful, they can cause significant side effects, requiring careful monitoring.

Ocular Harms: Steroid eye drops can cause intraocular hypertension (high pressure in the eye), which can lead to glaucoma if not managed ^[9]^[10]. They can also cause cataracts (clouding of the eye’s lens) ^[11].
Systemic Harms: Long-term oral steroids can increase infection risk, elevate blood pressure and blood sugar (hyperglycemia), and cause weakened bones/muscles (myopathy), mood changes, and a “Cushingoid” appearance (a rounded face and weight gain). In children, they can suppress growth ^[12]^[13].

Second-Line: Steroid-Sparing Agents

If steroids aren’t working well enough, or if the side effects are too severe, your doctor may suggest “steroid-sparing” medications. These drugs help keep the disease in remission so you can stop taking steroids ^[2]^[14].

Conventional Immunomodulators: Medications like Methotrexate, Mycophenolate Mofetil (MMF), or Azathioprine are often used. They take longer to start working but can be very effective. These require regular laboratory safety monitoring of your blood counts, liver, and kidney function, as well as infection screening. Discuss vaccination guidance and reproductive considerations with your doctor, as some of these carry severe pregnancy risks ^[2]^[15].
Biologics: For cases that are very difficult to treat (refractory), doctors may consider TNF inhibitors like Adalimumab or Infliximab ^[2]. While these have been used for persistent ocular inflammation in small observational reports (and may be used off-label), patients starting biologics require specialized screening for latent tuberculosis and hepatitis prior to treatment ^[13]^[16].

Long-Term Outlook

Many patients achieve a “quiescence”—a state where the disease is inactive—after a few months or years of treatment ^[17]. However, because relapses can happen long after you feel better, your care team will create an individualized plan to continue monitoring your kidney labs and eye exams ^[18]^[17].

Common questions in this guide

What medicines are usually used first to treat TINU syndrome?

Corticosteroids are usually the first treatment for TINU. Oral or intravenous steroids are used for kidney inflammation, while steroid eye drops commonly treat inflammation in the front of the eye; more extensive eye inflammation may need oral steroids or an injection near the eye.

What does a slow steroid taper mean for someone with TINU?

A slow taper means reducing the dose gradually over weeks or months rather than stopping suddenly. Oral steroids are tapered to let the adrenal glands recover and to lower relapse risk, while eye drops are reduced under an ophthalmologist’s direction to prevent eye inflammation from returning. Do not change either dose without instructions.

Can TINU eye inflammation return while steroids are being reduced?

Yes. About half of people with TINU may have a return of eye inflammation during or soon after a steroid taper. The kidneys and eyes can improve at different rates, so your doctor may use separate schedules for oral steroids and eye drops.

What side effects can TINU steroid treatment cause?

Steroid eye drops can raise pressure inside the eye and contribute to glaucoma or cataracts, so eye pressure and eye health need monitoring. Longer-term oral steroids can increase infection risk, blood pressure, blood sugar, mood or sleep changes, appetite and weight, and bone or muscle problems; children may have slowed growth.

When might steroid-sparing medicine be considered for TINU?

Your doctor may consider a steroid-sparing medicine when steroids do not control inflammation well enough or their side effects are too severe. Options for TINU include methotrexate, mycophenolate mofetil, and azathioprine; difficult-to-treat cases may be treated with biologic medicines such as adalimumab or infliximab. These treatments require blood tests and other safety screening.

What monitoring is needed during treatment for TINU?

Follow-up usually includes kidney blood tests and regular eye examinations, including checks of eye pressure when steroid drops are used. Medicines such as methotrexate, mycophenolate mofetil, or azathioprine require monitoring of blood counts, liver function, and kidney function, while biologics require screening for latent tuberculosis and hepatitis before treatment.

Get notified when new evidence is published on Tubulointerstitial nephritis and uveitis syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
Renal outcomes in tubulointerstitial nephritis and uveitis (TINU) syndrome: a systematic review and meta-analysis.
Southgate G, Clarke P, Harmer MJ
Journal of nephrology 2023; (36(2)):507-519 doi:10.1007/s40620-022-01478-8.
PMID: 36396848
2
Clinical outcomes in paediatric tubulointerstitial nephritis and uveitis syndrome (TINU).
Mandel M, Elhusseiny AM, Davidson SL, et al.
Eye (London, England) 2024; (38(17)):3318-3324 doi:10.1038/s41433-024-03286-9.
PMID: 39085599
3
Successful treatment of tubulointerstitial nephritis and uveitis with steroid and azathioprine in a 12-year-old boy.
Kim JE, Park SJ, Oh JY, et al.
Korean journal of pediatrics 2016; (59(Suppl 1)):S99-S102 doi:10.3345/kjp.2016.59.11.S99.
PMID: 28018458
4
Tubulointerstitial nephritis with uveitis (TINU) syndrome following COVID-19 vaccination in an elderly patient: a case report.
Takahashi S, Nagao N, Yoshida K, et al.
CEN case reports 2026; (15(1)):28 doi:10.1007/s13730-025-01047-5.
PMID: 41563636
5
Clinical Features and Treatment Outcomes of Patients with Tubulointerstitial Nephritis and Uveitis Syndrome: A Case Series.
Ruiz-Lozano RE, Liberman P, Zhao AT, et al.
Ocular immunology and inflammation 2026; (34(3)):464-472 doi:10.1080/09273948.2026.2621958.
PMID: 41719437
6
Clinical Profile, Ultra-Wide-Field Fluorescence Angiography Findings, and Long-Term Prognosis of Uveitis in Tubulointerstitial Nephritis and Uveitis Syndrome at One Tertiary Medical Institute in China.
Yang M, Chi Y, Guo C, et al.
Ocular immunology and inflammation 2019; (27(3)):371-379 doi:10.1080/09273948.2017.1394469.
PMID: 29190160
7
Tubulointerstitial Nephritis and Uveitis Syndrome: Characterization of Clinical Features.
Koreishi AF, Zhou M, Goldstein DA
Ocular immunology and inflammation 2021; (29(7-8)):1312-1317 doi:10.1080/09273948.2020.1736311.
PMID: 32463299
8
Real-world evidence of treatment for relapse of noninfectious uveitis in tertiary centers in Japan: A multicenter study.
Takeuchi M, Kanda T, Kaburaki T, et al.
Medicine 2019; (98(9)):e14668 doi:10.1097/MD.0000000000014668.
PMID: 30817592
9
Tubulointerstitial Nephritis With Uveitis (TINU) Syndrome: A Case Series and Review of Literature.
Ali W, Agrawal N, Sinha S, et al.
Nephrology (Carlton, Vic.) 2026; (31(9)):e70271 doi:10.1111/nep.70271.
PMID: 42660125
10
Bilateral decompression retinopathy after deep sclerectomy with mitomycin C in a child with tubulointerstitial nephritis and uveitis syndrome.
Muñoz-Negrete FJ, Díez-Álvarez L, Garcia CF, Rebolleda G
European journal of ophthalmology 2020; (30(3)):NP1-NP6 doi:10.1177/1120672119832177.
PMID: 30841750
11
An Overview of Pediatric Uveitis.
Tuğal-Tutkun İ
Turkish archives of pediatrics 2023; (58(4)):363-370 doi:10.5152/TurkArchPediatr.2023.23086.
PMID: 37357450
12
Successful long-term treatment of tubulointerstitial nephritis and uveitis with mycophenolate.
Qi L, Chandler S, Puri P, Hepburn K
BMJ case reports 2025; (18(11)) doi:10.1136/bcr-2025-266877.
PMID: 41198153
13
Early Initiation of TNF Inhibitors for Tubulointerstitial Nephritis and Uveitis (TINU).
Song BM, VanDevoorde R, Graham TB, Gangaputra S
Ocular immunology and inflammation 2025; 1-5 doi:10.1080/09273948.2025.2592067.
PMID: 41287192
14
Tubulointerstitial nephritis and uveitis in children during the COVID-19 pandemic: report of four cases.
Sakhinia F, Brice V, Ollerenshaw R, et al.
Journal of nephrology 2023; (36(5)):1451-1455 doi:10.1007/s40620-022-01564-x.
PMID: 36848016
15
Acute tubulointerstitial nephritis (ATIN) including drug-induced, tubulointerstitial nephritis and uveitis (TINU), ANCA-associated vasculitis (AAV), kidney- limited sarcoidosis, and hemolysis: a case series from Syria.
Alsultan M, Kliea M, Hassan Q
BMC nephrology 2025; (26(1)):97 doi:10.1186/s12882-025-04030-5.
PMID: 40000970
16
Adalimumab in refractory pediatric tubulointerstitial nephritis and uveitis syndrome: a case report of sustained renal-ocular remission and literature review.
Yang D, Xi W, Liu W, et al.
BMC nephrology 2025; (26(1)):609 doi:10.1186/s12882-025-04535-z.
PMID: 41184789
17
Long-term Follow-up of Patients with Tubulointerstitial Nephritis and Uveitis (TINU) Syndrome.
Sobolewska B, Bayyoud T, Deuter C, et al.
Ocular immunology and inflammation 2018; (26(4)):601-607 doi:10.1080/09273948.2016.1247872.
PMID: 27937079
18
Long-term outcome of biopsy-proven idiopathic tubulointersitial nephritis with or without uveitis in children-a nationwide follow-up study.
Rytkönen S, Tainio J, Saarela V, et al.
Pediatric nephrology (Berlin, Germany) 2021; (36(11)):3663-3671 doi:10.1007/s00467-021-05060-5.
PMID: 34008125

This page is for informational purposes only and does not constitute medical advice about TINU. Your nephrologist and ophthalmologist should guide steroid changes, side-effect monitoring, and decisions about other medicines.